Tirofiban (hydrochloride hydrate)

Tirofiban is a potent nonpeptide glycoprotein IIb/IIIa antagonist (GPIIb/IIIa, IC50 = 5 nM in a radioligand binding assay). It inhibits GPIIb/IIIa-dependent platelet aggregation with an IC50 value of 11 nM. Tirofiban is selective for platelet GPIIb/IIIa, only inhibiting human umbilical vein endothelial cell (HUVEC) attachment to microtiter plates containing fibrinogen (Fg), human vitronectin (Vn), or human fibronectin (Fn) at concentrations >10,000-fold above the IC50 for platelet aggregation. Tirofiban (300 and 1,000 µg/kg per minute, i.v.) prevents occlusive thrombosis and reduces thrombus mass in a canine model of electrically-induced coronary artery occlusive thrombosis. Formulations containing tirofiban have been used to prevent thrombotic occlusion associated with coronary angioplasty.Formal Name: N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine, monohydrochloride, monohydrate. CAS Number: 150915-40-5. Molecular Formula: C22H36N2O5S . HCl [H2O]. Formula Weight: 495.1. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: 30 mg/ml, Ethanol:PBS (pH7.2)(1:20): 0.05 mg/ml. lambdamax: 228, 277 nm. SMILES: O=C(O)[C@@H](NS(CCCC)(=O)=O)CC1=CC=C(OCCCCC2CCNCC2)C=C1.Cl.O. InChi Code: InChI=1S/C22H36N2O5S.ClH.H2O/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18,,/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26),1H,1H2/t21-,,/m0../s1. InChi Key: HWAAPJPFZPHHBC-FGJQBABTSA-N.